First-in-human phase 1/2 study (CA052-002) evaluating the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of imzokitug (BMS-986340), an anti-CCR8 monoclonal antibody (SITC 2026) - Oct 2, 2026 - Abstract #560; Pres time: Nov 7, 2026; 10:00 AM - 08:10 PM; Location: PCC - Lower Level - North Exhibition Halls 4-5-6; No abstract available
Clinical • First-in-human • P1/2 data • PK/PD data • Oncology • CCR8
|
|
Jay Oza; Matteo Simonelli; Yasutoshi Kuboki; Ignacio Melero; John Hilton; Aaron Hansen; Martin Wermke; Victor Moreno; Emiliano Calvo; Rahima Jamal; Cinta Hierro; Giulia Pretelli; Martin Gutierrez; Javier Garcia-Corbacho; Filippo De Braud; Luis Paz-Ares; Neelu Yadav; Nancy Van Prooyen; Lola Alakija; Akshay Sudhindra; Sai Bathena; Guotao Chu; Cyrus Sayehli
|